STOCK TITAN

Fulgent Genetics, Inc. - FLGT STOCK NEWS

Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a technology-driven company specializing in genetic testing, with the mission of making advanced genetic diagnostics accessible and affordable. Founded in 2011, Fulgent Genetics focuses on providing flexible and comprehensive genetic testing solutions aimed at improving everyday lives. The company operates through two primary segments: laboratory services and therapeutic development.

The laboratory services segment, which is the main revenue generator, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent Genetics offers a broad array of tests that cover various genetic disorders, helping clinicians and patients obtain clinically actionable diagnostic information.

The therapeutic development segment is dedicated to creating drug candidates for a broad range of cancers. Utilizing innovative nanoencapsulation and targeted therapy platforms, Fulgent aims to improve the pharmacokinetic profile and therapeutic window of new and existing cancer drugs.

One of the company's recent achievements is a partnership with CooperSurgical, enabling the addition of exclusive newborn genetic screening panels to the services offered by Cord Blood Registry® (CBR®), the largest private newborn stem cell preservation company globally.

Fulgent's Picture® Genetics, launched in 2019, provides consumers direct access to comprehensive genetic testing at home. The tests cater to various needs and offer clinically actionable, medical-grade results with professional oversight. This complements Fulgent's laboratory services by making genetic testing more accessible and user-friendly.

With its headquarters in El Monte, California, Fulgent Genetics continues to expand its reach, serving clients both in the United States and internationally. The company's commitment to excellence is reflected in its collaborations with top clinicians and continuous improvements to its testing panels and report formats.

Rhea-AI Summary

Fulgent Genetics, Inc. (NASDAQ: FLGT) announced its first quarter 2024 financial results, reporting a total revenue of $64.5 million with core revenue growing 1% year-over-year to $63.2 million. The company reiterated its full-year 2024 core revenue guidance of $280 million. Despite a GAAP loss of $13.5 million, or $0.45 per share, Fulgent showed a non-GAAP loss of $269,000, or $0.01 per share. The adjusted EBITDA loss was $3.2 million, with cash from operations at $7.3 million. Fulgent's cash, cash equivalents, and investments in marketable securities were $846.2 million as of March 31, 2024. The company highlighted strong momentum in Precision Diagnostics and milestones in its therapeutic development business, including progress in clinical testing for lead oncology drug candidate FID-007. Fulgent maintains a positive outlook for the full year 2024, expecting core revenue of approximately $280 million and a strong financial position with ample cash to execute.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
-
Rhea-AI Summary
Fulgent Genetics, Inc. (FLGT) will release its first quarter 2024 financial results on May 3, 2024. The company, known for its laboratory services and therapeutic development business, will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
-
Rhea-AI Summary
Fulgent Genetics, Inc. (FLGT) reports Full Year 2023 Total Revenue of $289.2 million, with Core Revenue growing 44% year-over-year to $262.1 million. The company ended 2023 with $847.7 million in cash, cash equivalents, and investments in marketable securities. Despite a GAAP loss of $167.8 million for the full year, Fulgent showcased progress in its core business and therapeutic development ventures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.14%
Tags
Rhea-AI Summary
Fulgent Genetics, Inc. (FLGT) announces the release of its Q4 and full year 2023 financial results on February 28, 2024. The company, known for its clinical diagnostic and therapeutic development businesses, will host a conference call to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.81%
Tags
-
Rhea-AI Summary
COO announces testing services for CBR families to proactively seek additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Fulgent Genetics, Inc. (NASDAQ: FLGT) to Participate in Piper Sandler 35th Annual Healthcare Conference. The company's management team will conduct a presentation on November 28, 2023, with a live webcast available on the Investor Relations section of the Fulgent Genetics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences
Rhea-AI Summary
Fulgent Genetics announces data from two poster presentations at the Society for Immunotherapy of Cancer Annual Meeting. The first poster explores the role of liquid biopsy technology in comparing ctDNA variants in plasma and tissue. The second poster highlights progress for Fulgent Pharma's lead therapeutic candidate, FID-007, in various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
Rhea-AI Summary
Fulgent Genetics, Inc. (NASDAQ: FLGT) reported total revenue of $85 million for Q3 2023, with core revenue growing 17% YoY to $66 million. The company generated a GAAP loss of $13.1 million and a non-GAAP loss of $11.7 million. Adjusted EBITDA was $18.1 million, and cash flow from operations was $10.2 million. Fulgent maintains a strong financial profile with $851 million in cash, cash equivalents, and investments in marketable securities as of September 30, 2023. The company reiterates its full-year 2023 core revenue guidance of $260 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.24%
Tags
-
Rhea-AI Summary
Fulgent Genetics announces two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The presentations will focus on critical clinical evaluation of plasma to tumor tissue concordance by cancer type and a novel nano-drug delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
Rhea-AI Summary
Fulgent Genetics to release Q3 2023 financial results on November 3, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags

FAQ

What is the current stock price of Fulgent Genetics (FLGT)?

The current stock price of Fulgent Genetics (FLGT) is $19.7 as of December 5, 2024.

What is the market cap of Fulgent Genetics (FLGT)?

The market cap of Fulgent Genetics (FLGT) is approximately 607.5M.

What does Fulgent Genetics, Inc. do?

Fulgent Genetics specializes in genetic testing and therapeutic development, providing clinicians with clinically actionable diagnostic information.

When was Fulgent Genetics founded?

Fulgent Genetics was founded in 2011.

What are the main segments of Fulgent Genetics' business?

The main segments are laboratory services and therapeutic development.

What recent partnership has Fulgent Genetics entered into?

Fulgent Genetics has partnered with CooperSurgical to offer exclusive newborn genetic screening panels via Cord Blood Registry®.

What is Picture® Genetics?

Picture® Genetics is a consumer-focused service launched by Fulgent Genetics that offers at-home genetic testing with comprehensive, clinically actionable results.

Where is Fulgent Genetics headquartered?

Fulgent Genetics is headquartered in El Monte, California.

What is the focus of Fulgent's therapeutic development segment?

The therapeutic development segment focuses on developing drug candidates for treating various cancers using innovative technologies.

How does Fulgent Genetics ensure the quality of its genetic tests?

Fulgent collaborates with top clinicians and continuously improves its testing panels and report formats to ensure high-quality results.

How does Fulgent Genetics make genetic testing accessible?

Fulgent offers flexible and affordable testing solutions and has consumer-focused services like Picture® Genetics to make testing accessible from home.

What is the primary revenue source for Fulgent Genetics?

The primary revenue source is their laboratory services, including technical lab services and professional interpretation of results by licensed physicians.

Fulgent Genetics, Inc.

Nasdaq:FLGT

FLGT Rankings

FLGT Stock Data

607.45M
20.70M
32.32%
54.29%
1.89%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
EL MONTE